Enhancing Effectiveness of drugs Against Prostate Cancer


Although nucleotide drugs offer advantages in treating tumors and other diseases, they often suffer from a poor efficiency of crossing the blood vessels and entering the tumor tissue, where their targets reside. This problem greatly limits their clinical applicability and efficacy.


“Our system demonstrates a good ability to deliver more ASOs into both primary tumor tissue and bone metastases — which is the primary site for prostate cancer metastasis,” said Pang, an assistant professor in the College of Pharmacy and a member of the Masonic Cancer Center.

“This further translates into a significant improvement of ASO efficacy to inhibit the growth of primary tumor and bone metastases. We expect this system to become a universal carrier system, to improve the clinical efficacy of ASOs and other nucleotide drugs.”

Findings of the study:

  • iRGD-liposomes can raise the tumor accumulation and vascular/tissue penetration of ASOs against the disease-driving gene of prostate cancer;

  • the ability of ASOs to inhibit the growth of both primary tumors and bone metastases was significantly enhanced by iRGD-liposomes;

  • and, a long-term tumor inhibition study was also performed, showing that iRGD-liposomes significantly prolongs the AR-ASO suppression of primary tumor growth.

  • Pang and his team say that iRGD-liposomes are proven as a desirable delivery system for ASOs, and hold the promise to improve the clinical efficacy of nucleotide drugs in cancer therapies.

    Source: Medindia



    • Source link